Merck's Roger Perlmutter continues spinning deals, putting up $1B+ for Janux Therapeutics and its T cell engagers
Even as his tenure at Merck comes to a close, Roger Perlmutter isn’t finished wheeling and dealing just yet.
Less than a month after betting big on OncoImmune’s experimental Covid-19 drug in a $425 million buyout, Merck announced Friday morning that it’s plunking down $1 billion-plus to collaborate with small San Diego biotech Janux Therapeutics on T cell engagers. The pair will team up on two cancer targets selected by Merck, with Janux eligible for up to $500.5 million in upfront and milestone payments per target.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.